Compare MLCO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | NBTX |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Hong Kong | France |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2006 | 2018 |
| Metric | MLCO | NBTX |
|---|---|---|
| Price | $4.66 | $33.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.10 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.6M | 133.2K |
| Earning Date | 04-30-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.42 | $58.17 |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $12.63 |
| 52 Week High | $9.90 | $57.14 |
| Indicator | MLCO | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 37.36 |
| Support Level | N/A | $30.15 |
| Resistance Level | $5.73 | $34.66 |
| Average True Range (ATR) | 0.17 | 1.95 |
| MACD | -0.05 | -0.68 |
| Stochastic Oscillator | 14.95 | 0.50 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.